Compare iShares MSCI France ETF (EWQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI France ETF trades at $47.51, while Recursion Pharmaceuticals Inc trades at $3.28 (market cap $1.81B). The key difference: iShares MSCI France ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EWQ | RXRX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $6.79 |
52-Week Low | $41.68 | $2.84 |
Market Cap | — | $1.81B |
Enterprise Value | — | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ, the iShares MSCI France ETF, trades at $47.505, down 0.51% on the day, with a bullish technical signal driven by moving averages. The ETF focuses on French equities, particularly industrials, and offers a dividend scheduled for June 2026. Recent news highlights ECB rate decisions and French tech investments, influencing sentiment.
The outlook for EWQ is supported by bullish technicals and positive analyst views on French stocks, but risks include ECB policy shifts and geopolitical tensions. Investors may find opportunity in Europe's cyclical recovery, though volatility from energy prices and economic data poses challenges.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
